HSA
JNCE

Hussman Strategic Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Hussman Strategic Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,500
Closed -$105K – 364
2021
Q2 		$105K Buy
+15,500
New +$129K 0.02% 326
2021
Q1 		– Sell
-51,000
Closed -$357K – 367
2020
Q4 		$357K Sell
51,000
-51,000
-50% -$397K 0.09% 247
2020
Q3 		$832K Buy
+102,000
New +$632K 0.22% 167

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Hussman Strategic Advisors's JNCE Position: Q3 2021 in Review

Hussman Strategic Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 15,500 shares — an estimated $105K sold.

Hussman Strategic Advisors first reported a position in JNCE in Q3 2020 and held it in 3 quarters. The position peaked at $832K in Q3 2020. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • Hussman Strategic Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Hussman Strategic Advisors sold 15,500 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $105K.
  • Hussman Strategic Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Hussman Strategic Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $832K in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Hussman Strategic Advisors's 13F filing for Q3 2021, filed 1 Nov 2021.